Neuraly, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company's lead candidate, NLY01, is a novel glucagon-like peptide-1 receptor (GLP-1R) agonist designed to protect dopaminergic neurons and halt disease progression[1].
| Attribute | Details |
|---|---|
| Founded | 2016 |
| Headquarters | South Korea (Seoul) / USA |
| CEO | Dr. Kwang-Soo Kim |
| Sector | Biotechnology |
| Focus | Neurodegenerative diseases |
Neuraly's approach centers on GLP-1 receptor activation in the brain. GLP-1R agonists have shown neuroprotective properties in multiple preclinical models of Parkinson's disease and Alzheimer's disease[2].
Mechanism of Action:
Unlike antibody-based approaches targeting alpha-synuclein aggregation, NLY01 works through a receptor-mediated mechanism that modulates the brain's immune response and protects neurons from toxic species.
| Attribute | Details |
|---|---|
| Target | GLP-1 Receptor |
| Mechanism | Neuroprotection, astrocyte modulation |
| Route | Subcutaneous injection |
| Phase | Phase 2 |
| Trial ID | NCT05024240 |
A 36-week, randomized, double-blind, placebo-controlled Phase 2 trial evaluated NLY01 in participants with early untreated Parkinson's disease at 58 U.S. movement disorder clinics[3].
Trial Results:
| Program | Target | Indication | Status |
|---|---|---|---|
| NLY02 | GLP-1R | Alzheimer's disease | Preclinical |
| NLY03 | GLP-1R | ALS | Discovery |
Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated neuroprotective effects in multiple studies:
NLY01 specifically targets the pathological communication between microglia and astrocytes:
| Company | Drug | Mechanism | Phase |
|---|---|---|---|
| Neuraly | NLY01 | GLP-1R agonist | Phase 2 |
| Denali/Biogen | DNL151 | LRRK2 inhibitor | Phase 2b |
| Prothena | Prasinezumab | Anti-α-syn antibody | Phase 2 |
| Vaxxinity | UB-312 | α-syn vaccine | Phase 2 |